Skip to search formSkip to main contentSkip to account menu

crofelemer

An oligomeric proanthocyanidin extracted from the latex produced by the tree Croton lechleri (Euphorbiaceae), with antidiarrheal, and potential… 
National Institutes of Health

Related topics

Related topics

7 relations
AntidiarrhealsDiarrheacrofelemer 125 MG Delayed Release Oral Tablet [Fulyzaq]crofelemer 125 MG Delayed Release Oral Tablet [Mytesi]

Broader (1)

Proanthocyanidins

Narrower (2)

ProvirSP 303

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
HIV and diarrhoea: what is new?
Purpose of review The review examines the changing causes and the investigation of infectious and noninfectious diarrhoea in… 
2016
2016
From plants to pharmacy shelf: natural products revival
2015
2015
Effect of crofelemer extract on severity and consistency of experimentally induced enterotoxigenic Escherichia coli diarrhea in newborn Holstein calves.
The objective of this study was to evaluate the effect of a standardized botanical extract of Croton lechleri, named crofelemer… 
2015
2015
Profile of crofelemer for the symptomatic treatment of diarrhea in HIV-infected persons
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of… 
Review
2014
Review
2014
Crofelemer: In HIV Associated Diarrhea and Secretory Diarrhea - A Patent Perspective.
PURPOSE Diarrhea and dehydration caused by enteric infections is a major factor of morbidity and mortality worldwide. Secretory… 
2014
2014
Practical Considerations for a Two-Stage Confirmatory Adaptive Clinical Trial Design and Its Implementation: ADVENT Trial
In this chapter, we provide the details of an innovative two-stage, seamless adaptive clinical trial called ADVENT. This trial… 
2014
2014
Vortioxetine hydrobromide, crofelemer, and teduglutide.
2013
2013
Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea.
Secretory diarrhea has a significant impact on morbidity and mortality worldwide and may be a predominant or minor component of… 
2013
2013
Crofelemer Is Approved for Noninfectious Diarrhea in HIV-Infected Patients
On December 31, 2012, the FDA announced the approval of crofelemer (Fulyzaq) to relieve symptoms of noninfectious diarrhea in HIV… 
2008
2008
Evaluation of Crofelemer in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Patients
Background: Crofelemer improves bowel function in several conditions characterized by states of prominent secretory diarrhea. Aim… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)